AC
BIO icon

Avestar Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

Avestar Capital’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-582
Closed -$201K – 462
2024
Q1 		$201K Buy
+582
New +$191K 0.02% 426
2023
Q4 		– Sell
-599
Closed -$215K – 402
2023
Q3 		$215K Buy
+599
New +$231K 0.03% 316
2018
Q3 		– Sell
-3
Closed – – 838
2018
Q2 		$0 Hold
3
– – ﹤0.01% 880
2018
Q1 		$0 Buy
+3
New +$764 ﹤0.01% 835

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Avestar Capital's BIO Position: Q2 2024 in Review

Avestar Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2024, closing a stake of 582 shares — an estimated $201K sold.

Avestar Capital first reported a position in BIO in Q1 2018 and held it in 4 quarters. The position peaked at $215K in Q3 2023. 440 funds tracked by Wall St. Rank hold BIO as of Q2 2024.

  • Avestar Capital reported no remaining Bio-Rad Laboratories Class A position as of Q2 2024 after selling out during the quarter.
  • Avestar Capital sold 582 Bio-Rad Laboratories Class A shares in Q2 2024, an estimated $201K.
  • Avestar Capital first reported a position in Bio-Rad Laboratories Class A in Q1 2018 and held it in 4 quarters.
  • Avestar Capital's Bio-Rad Laboratories Class A position peaked at $215K in Q3 2023.
  • 440 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2024.

Based on Avestar Capital's 13F filing for Q2 2024, filed 8 Aug 2024.